Skip to content
    RVMD stock page

    Revolution Medicines, Inc.

    RVMD · earnings call history

    4 calls analysed
    1. Mar 2026Q1 FY26May 06, 2026

      Revolution Medicines Q1 FY26 — Daraxonrasib Shows Unprecedented OS Benefit in Pancreatic Cancer

      Read the brief
    2. Dec 2025Q4 FY25Feb 25, 2026

      Revolution Medicines Q4 FY25 — Pipeline Advancement and Commercialization Readiness

      Read the brief
    3. Sep 2025Q3 FY25Nov 05, 2025

      Revolution Medicines Q3 FY25 — Daraxonrasib Pancreatic Cancer Progress & Pipeline Expansion

      Read the brief
    4. Dec 2024Q4 FY24Feb 26, 2025

      Revolution Medicines Q4 FY24 — Advancing RAS(ON) Inhibitor Pipeline with Multiple Pivotal Trials

      Read the brief

    Browse all US companies on the earnings-call register.